<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002118</url>
  </required_header>
  <id_info>
    <org_study_id>200801761</org_study_id>
    <nct_id>NCT01002118</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients</brief_title>
  <official_title>Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease and mortality is the largest comorbidity within the dialysis
      population. Nearly 50% of hemodialysis patients will have congestive heart failure at
      initiation. According to the most recent United States Renal Data System (USRDS), 40% of
      incident dialysis patients will have a cardiovascular event or die within the first 9 months
      of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial
      cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3
      fatty acid doses on cardiovascular parameters in an incident hemodialysis population.
      Initially, this will be a pilot study. Ultimately, the information will be used to
      adequately plan for a larger intervention trial using Omega-3 fatty acids in incident
      hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit eligible subjects; no data analyzed
  </why_stopped>
  <start_date type="Actual">January 25, 2008</start_date>
  <completion_date type="Actual">February 23, 2011</completion_date>
  <primary_completion_date type="Actual">February 23, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine recruitment and medication adherence rates</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effectiveness of Omega-3 fatty acid compared to placebo on electrocardiographic parameters.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules each day for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Acid Ethyl Esters</intervention_name>
    <description>1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
    <arm_group_label>Omega-3 Fatty Acid</arm_group_label>
    <other_name>Lovaza 4g capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 capsules each day for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Initiated dialysis in past 3 months

          -  Signed informed consent

          -  Attending University of Iowa dialysis unit for duration of the study

        Exclusion Criteria:

          -  Age &gt;70

          -  Unable to provide consent

          -  Currently taking fish oil supplementation

          -  rhythm other than sinus

          -  implantable cardioverter-defibrillator

          -  pacemaker

          -  myocardial infarction,revascularization or unstable angina in past 3 months

          -  other hospitalization in past 3 months

          -  symptomatic heart failure

          -  known left ventricular ejection fraction &lt; 30%

          -  history of a significant bleeding disorder

          -  severe bleeding episode requiring hospitalization in past 3 months (GI bleed or
             hemorrhagic stroke)

          -  unexplained HgB drop &gt; 2 gm/dl in past 3 months

          -  chronic warfarin or anti-coagulation therapy (such as Lovenox)

          -  pregnant or nursing mothers

          -  allergic to fish, fish oil or fish products

          -  Participation in other trials of investigational products

          -  other characteristics as determined by the investigator that would make sudy
             participation inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>October 23, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Jennifer G. Robinson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>heart rate variability</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
